53
The financing was led by new investors ORI Healthcare Fund L.P. (“ORI Fund”) with participation by Shenzhen Hepalink Pharmaceutical Co., Ltd. Already, Kymab can count some of the biggest name in biotech investment among its backers: Wellcome Trust, Bill & Melinda Gates Foundation, Malin Corporation plc, CF Woodford Equity Income Fund and Woodford Patient Capital plc participated in follow-on investments.
With the money, Kymab plans to advance its pipeline of therapeutic human monoclonal antibodies, which have been developed with the company’s proprietary Kymouse transgenic antibody platform. Its most advanced compound is KY1005, for the…